Hepatic Expression of Candidate Genes in Patients With Alcoholic Hepatitis: Correlation With Disease Severity

Gastroenterology

Volumn 132, Issue 2, 2007, Pages 687-697

  Colmenero, Jordi ^a   Bataller, Ramón ^a   Sancho Bru, Pau ^a   Bellot, Pablo ^a   Miquel, Rosa ^b   Moreno, Montserrat ^a   Jares, Pedro ^c   Bosch, Jaime ^a   Arroyo, Vicente ^a   Caballería, Joan ^a   Ginès, Pere ^a  

^a Institut Clinic de Malalties Digestives i Metaboliques   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847039276     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.12.036     Document Type: Article

References (41)

1. McCullough A.J., and O'Connor J.F. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 93 (1998) 2022-2036
2. Mathurin P., Abdelnour M., Ramond M.J., Carbonell N., Fartoux L., Serfaty L., Valla D., Poupon R., Chaput J.C., and Naveau S. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 38 (2003) 1363-1369
3. Parés A., Caballería J., Bruguera M., Torres M., and Rodés J. Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 2 (1986) 33-42
4. Carithers Jr. R.L., Herlong H.F., Diehl A.M., Shaw E.W., Combes B., Fallon H.J., and Maddrey W.C. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 110 (1989) 685-690
5. Srikureja W., Kyulo N.L., Runyon B.A., and Hu K.Q. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 42 (2005) 700-706
6. Mathurin P., Mendenhall C.L., Carithers Jr. R.L., Ramond M.J., Maddrey W.C., Garstide P., Rueff B., Naveau S., Chaput J.C., and Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 36 (2002) 480-487
7. Tilg H., Jalan R., Kaser A., Davies N.A., Offner F.A., Hodges S.J., Ludwiczek O., Shawcross D., Zoller H., Alisa A., Mookerjee R.P., Graziadei I., Datz C., Trauner M., Schuppan D., Obrist P., Vogel W., and Williams R. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 38 (2003) 419-425
8. Spahr L., Rubbia-Brandt L., Frossard J.L., Giostra E., Rougemont A.L., Pugin J., Fischer M., Egger H., and Hadengue A. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 37 (2002) 448-455
9. Naveau S., Chollet-Martin S., Dharancy S., Mathurin P., Jouet P., Piquet M.A., Davion T., Oberti F., Broet P., and Emilie D. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39 (2004) 1390-1397
10. Tsukamoto H., and Lu S.C. Current concepts in the pathogenesis of alcoholic liver injury. FASEB J 15 (2001) 1335-1349
11. de la M.H., Lieber C.S., DeCarli L.M., French S.W., Lindros K.O., Jarvelainen H., Bode C., Parlesak A., and Bode J.C. Models of alcoholic liver disease in rodents: a critical evaluation. Alcohol Clin Exp Res 25 (2001) 254S-261S
12. Bird G.L., Sheron N., Goka A.K., Alexander G.J., and Williams R.S. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 112 (1990) 917-920
13. Sheron N., Bird G., Goka J., Alexander G., and Williams R. Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol 84 (1991) 449-453
14. Sheron N., Bird G., Koskinas J., Portmann B., Ceska M., Lindley I., and Williams R. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology 18 (1993) 41-46
15. Mookerjee R.P., Sen S., Davies N.A., Hodges S.J., Williams R., and Jalan R. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 52 (2003) 1182-1187
16. Fujimoto M., Uemura M., Nakatani Y., Tsujita S., Hoppo K., Tamagawa T., Kitano H., Kikukawa M., Ann T., Ishii Y., Kojima H., Sakurai S., Tanaka R., Namisaki T., Noguchi R., Higashino T., Kikuchi E., Nishimura K., Takaya A., and Fukui H. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol Clin Exp Res 24 (2000) 48S-54S
17. Shackel N.A., Gorrell M.D., and McCaughan G.W. Gene array analysis and the liver. Hepatology 36 (2002) 1313-1325
18. Honda M., Kaneko S., Kawai H., Shirota Y., and Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 120 (2001) 955-966
19. Asselah T., Bieche I., Laurendeau I., Paradis V., Vidaud D., Degott C., Martinot M., Bedossa P., Valla D., Vidaud M., and Marcellin P. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 129 (2005) 2064-2075
20. Honda M., Kawai H., Shirota Y., Yamashita T., Takamura T., and Kaneko S. cDNA microarray analysis of autoimmune hepatitis, primary biliary cirrhosis and consecutive disease manifestation. J Autoimmun 25 (2005) 133-140
21. Paradis V., Bieche I., Dargere D., Cazals-Hatem D., Laurendeau I., Saada V., Belghiti J., Bezeaud A., Vidaud M., Bedossa P., and Valla D.C. Quantitative gene expression in Budd-Chiari syndrome: a molecular approach to the pathogenesis of the disease. Gut 54 (2005) 1776-1781
22. Shackel N.A., McGuinness P.H., Abbott C.A., Gorrell M.D., and McCaughan G.W. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol 160 (2002) 641-654
23. Smith M.W., Yue Z.N., Korth M.J., Do H.A., Boix L., Fausto N., Bruix J., Carithers Jr. R.L., and Katze M.G. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 38 (2003) 1458-1467
24. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1 (1981) 707-711
25. Turnes J., Hernández-Guerra M., Abraldes J.G., Bellot P., Oliva R., Garcia-Pagán J.C., and Bosch J. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Hepatology 43 (2006) 34-41
26. Michalak S., Rousselet M.C., Bedossa P., Pilette C., Chappard D., Oberti F., Gallois Y., and Cales P. Respective roles of porto-septal fibrosis and centrilobular fibrosis in alcoholic liver disease. J Pathol 201 (2003) 55-62
27. Kage M., Shimamatu K., Nakashima E., Kojiro M., Inoue O., and Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology 25 (1997) 1028-1031
28. Arteel G., Marsano L., Mendez C., Bentley F., and McClain C.J. Advances in alcoholic liver disease. Best Pract Res Clin Gastroenterol 17 (2003) 625-647
29. Simon R., Radmacher M.D., Dobbin K., and McShane L.M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95 (2003) 14-18
30. Radmacher M.D., McShane L.M., and Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol 9 (2002) 505-511
31. Colombat M., Charlotte F., Ratziu V., and Poynard T. Portal lymphocytic infiltrate in alcoholic liver disease. Hum Pathol 33 (2002) 1170-1174
32. Younossi Z.M., Baranova A., Ziegler K., Del Giacco L., Schlauch K., Born T.L., Elariny H., Gorreta F., VanMeter A., Younoszai A., Ong J.P., Goodman Z., and Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 42 (2005) 665-674
33. Anderson S. Role of local and systemic angiotensin in diabetic renal disease. Kidney Int Suppl 63 (1997) S107-S110
34. Gujral J.S., Hinson J.A., Farhood A., and Jaeschke H. NADPH oxidase-derived oxidant stress is critical for neutrophil cytotoxicity during endotoxemia. Am J Physiol 287 (2004) G243-G252
35. Reinehr R., Becker S., Eberle A., Grether-Beck S., and Haussinger D. Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. J Biol Chem 280 (2005) 27179-27194
36. Kono H., Rusyn I., Yin M., Gabele E., Yamashina S., Dikalova A., Kadiiska M.B., Connor H.D., Mason R.P., Segal B.H., Bradford B.U., Holland S.M., and Thurman R.G. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest 106 (2000) 867-872
37. Koch A.E., Kunkel S.L., Shah M.R., Hosaka S., Halloran M.M., Haines G.K., Burdick M.D., Pope R.M., and Strieter R.M. Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 155 (1995) 3660-3666
38. Podolin P.L., Bolognese B.J., Foley J.J., Schmidt D.B., Buckley P.T., Widdowson K.L., Jin Q., White J.R., Lee J.M., Goodman R.B., Hagen T.R., Kajikawa O., Marshall L.A., Hay D.W., and Sarau H.M. A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol 169 (2002) 6435-6444
39. Stefanovic L., Brenner D.A., and Stefanovic B. Direct hepatotoxic effect of KC chemokine in the liver without infiltration of neutrophils. Exp Biol Med 230 (2005) 573-586
40. Maltby J., Wright S., Bird G., and Sheron N. Chemokine levels in human liver homogenates: associations between GRO alpha and histopathological evidence of alcoholic hepatitis. Hepatology 24 (1996) 1156-1160
41. Quinn M.T., and Gauss K.A. Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol 76 (2004) 760-781